Close

People

Professor Adil Mardinoglu (Principal Investigator)
Email: [email protected]; [email protected]

Professor Adil Mardinoglu is an expert in the field of Systems Medicine, Systems Biology, Computational Biology and Bioinformatics. He has been recruited as a Professor of Systems Biology in Center for Host-Microbiome Interactions, King’s College London, UK where he leads a computational group. He also works as group leader in Science for Life Laboratory (Scilifelab), KTH-Royal Institute of Technology in Sweden and led a team of 25 researchers working in the area of computational biology, experimental biology and drug development to develop new treatment strategies for Metabolic diseases, Neurodegenerative diseases and certain type of cancers.

Professor Mardinoglu received his Bachelor’s degree from Istanbul Technical University, Turkey in Electronic and Telecommunication Engineering and his Ph.D. from Waterford Institute of Technology, Ireland in magnetic drug targeting applications. He worked as a postdoctoral researcher at Trinity College Dublin, Ireland and Chalmers University of Technology, Gothenburg, Sweden. His recent research activities include the generation of the context specific genome-scale metabolic models (GEMs) for human cell-types including liver, adipose, muscle, heart, kidney and brain as well as certain types of cancer e.g liver, kidney, colon, prostate and brain (glioblastoma) cancers. His research team also focuses on the integration of GEMs with the other biological networks including regulatory, protein-protein interactions and signaling networks. He employs comprehensive biological networks for revealing the molecular mechanisms of complex diseases, identification of novel biomarkers and drug targets and eventually development of efficient treatment strategies.

Professor Mardinoglu has contributed to the creation of human tissue, subcellular and pathology atlas within the Swedish Human Protein Atlas program and cell atlas within the international Human Cell Atlas program. He has published around 100 research and review papers in different journals including Science, Cell Metabolism, Nature Communications, PNAS, Cell Reports, Molecular Systems Biology and EbioMedicine. He is also co-founder of three different biotech companies focusing on the development of novel drugs for fatty liver disease and different cancer types.


SENIOR RESEARCHERS


Dr. Cheng Zhang (Group Leader) @SciLifeLab
Email: [email protected]

Dr. Cheng Zhang is a senior researcher and the group leader of Single Cell Medicine lab at Science for Life Laboratory. He has conducted the creation of Human Pathology Atlas as well as the Human Cell Type Atlas projects within the Swedish Human Protein Atlas program.
The rapid development of single cell omics technology has opened a new possibility of precision and translational medicine. The Single Cell Medicine group mainly focuses on integration and interpretation of single cell omics data with the help of systems biology tools such as multi-omics networks and genome-scale metabolic models. The aim is to reveal molecular mechanisms of complex disease whose development and progression may involve interplays with multiple cell types. In addition, key pathways and hub genes will also be identified which could be used as novel biomarkers or drug targets for diagnosis and treatment of individual patients. Currently, his group works on projects that investigate liver cirrhosis, renal fibrosis, and colon cancer.


POSTDOCTORAL FELLOWS 


Dr. Woonghee Kim @SciLifeLab
Email: [email protected]

Dr. Woonghee Kim received his Ph.D. degree in Chemical biology at Life Sciences Department, Gwangju Institute of Science and Technology, South Korea. He researched drug discovery and development that find new drugs to diseases, such as cancer, diabetes, myocardial infarction, and chemically induced stem cell therapy. He participated in a number of projects that developing anti-cancer new drug via glycolytic enzyme inhibition. Here, in Mardinoglu lab at SciLifeLab, Sweden, he is working on PKL targeting new molecules to cure hepatocellular carcinoma (HCC) and non-alcoholic steatohepatitis ( NASH).


Dr. Xiangyu Li @SciLifeLab
Email: [email protected]

XiangYuDr. Xiangyu Li received her M.Sc. and Ph.D. in Bioinformatics from the Fujian Medical University, China. During her Ph.D. period, she focused on identifying metastasis and drug benefit predictive signatures at the individual level for caner patients and explored the genomic and epigenomic alternation of patients using the multi-omics data. She also developed a new algorithm of differential expression analysis for the small-scale cell line experiments. Currently, she is working on identifying classification signature for liver cancer based on metabolic difference.

 


Dr. Ozlem Altay @SciLifeLab
Email:
[email protected]

Dr. Ozlem Altay, MD, Spec.,PhD is an expert in clinical microbiology and bioinformatics. Her main interest is to describe the functional signatures of the microbiota of metabolic diseases. Following university studies attempting molecular and phenotypic descriptions of clinical pathogens, she joined Mardinoglu’s team for developing research studies to decipher the impact of microbiota on human health. She is expanding her expertise by using novel systems biology methodologies such as integrated networks, genome scale metabolic models and related multi-omics approaches.
 


Dr. Ko Eun Shong @SciLifeLab
Email: [email protected]

Ko Eun Shong received Ph.D. degree in Biomedical Science and Engineering Interdisciplinary Program at Korea Advanced Institution of Science and Technology (KAIST), South Korea. Her research focused on the role of adipose-derived serotonin in regulating energy metabolism and adipocyte remodeling. She is currently working as a post-doctoral researcher in this group.
 
 


Dr. Han Jin @SciLifeLab
Email: [email protected]

Hanjin

Dr. Han Jin received his Bachelor’s degree from Tianjin University of Science and Technology (China) and Master’s degree from Nankai University (China), both in Computer Science. After that, he visited the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany for one year, and subsequently received his PhD degree from the Faculty of Health, Medicine and Life Sciences of Maastricht University, the Netherlands. His research interests focus on computational modelling of cardiovascular diseases. In carrying out above researches, he applies various omics technologies and computational approaches including multi-omics integration, single-cell sequencing, network analysis, machine learning, feature selection and drug repurposing, to understand the mechanism of atherosclerosis and to identify novel drug targets for cardiovascular diseases.


Dr. Mehmet Ozcan @SciLifeLab
Email: [email protected]

MehmetOzcan

Mehmet Ozcan received his B.Sc. degree in Chemistry from Cukurova University and his M.Sc. and Ph.D. degrees in Medical Biochemistry from Hacettepe University, Turkey in 2021. In his Ph.D. project, he focused on antioxidant systems and drug discovery for drug resistance in breast cancer treatment in vivo / vitro. During his Ph.D., he was granted by the Scientific and Technological Research Council of Turkey and he carried out further research about the effects of antioxidant use in breast cancer treatment via transcriptomic methods at Sysmedicine Lab between 2019- 2020. Additionally, he worked as a visiting scholar for a project aiming to produce and purify recombinant protein isoforms at the Bengt Mannervik laboratory, Stockholm University. In addition to his thesis projects, he has been involved in various studies such as A single cell type transcriptomics map of human tissues (Science Advances, 2021), The acute effect of metabolic cofactor supplementation: a potential therapeutic strategy against non‐alcoholic fatty liver disease (Molecular Systems Biology, 2020). His latest studies are published at Journal of Cellular Biochemistry 2019, Advanced Biosystems 2020, Biological Trace Element Research 2021. Currently, he focuses on drug discovery and validation studies for variable diseases such as NAFLD, skin aging, liver cancer, prostate cancer and kidney cancer.


Dr. Lingqi Meng @SciLifeLab
Email: [email protected]

Lingqi

Lingqi Meng received his Ph.D. degree in mathematics at the University at Buffalo, United States. He also earned a statistics bachelor’s degree from Nankai University, China. Lingqi has research experience in network science, epidemic modeling, and evolutionary games with mathematical and statistical methods. He focuses on developing new network algorithms to integrate and interpret the omics data. He aims to find significant biomarkers to deal with metabolomic diseases, such as Alzheimer’s disease.
 


PHD STUDENTS


Abdulahad Bayraktar @King’s College London
Email:
[email protected]

Abdulahad Bayraktar is a Molecular Biology and Genetics graduate from Middle East Technical University. Later, He received his MSc degree in Bioinformatics. During his MSc studies, he joined several research projects as a bioinformatician in the medical research centre at Istanbul Medipol University. Here he implemented and developed a variant discovery pipeline for rare disease diagnosis, which is being used for the diagnosis of hundreds of patients.
In the Mardinoglu Lab in King’s College London, he works on the discovery of biomarkers for diagnosis and novel drug targets for effective treatment of Alzheimer’s disease. He employs a systems biology approach assisted with machine learning (e.g. deep learning) in his research.


Hong Yang @SciLifeLab
Email:
[email protected]

Hong Yang received her Bachelor’s degree in Bioinformatics and Master’s degree in Pharmaceutical Science from Chongqing University (China). Currently, her project is developing novel computational methods to integrate GEMs (genome-scale metabolic models) with other biological networks and then apply these approaches to get insights into the molecular mechanism of metabolic diseases.
 
 
 


Meng Yuan @SciLifeLab
Email:
[email protected]

Meng Yuan graduated from The North University of China with B.Eng. in Biomedical Engineering and Tianjin Medical University with MSE. in Biomedical Engineering (Bioinformatics). She has been working on several projects including comorbidity symptom network analysis, drug repositioning, and nucleotide polymorphisms related to neurodegenerative diseases. In her doctoral study, she will conduct several research projects including molecular diagnosis, stratification of stomach cancer, and pathology atlas analysis.

 


Ali Kaynar @King’s College London
Email:
[email protected]

Ali Kaynar received a bachelor’s degree in molecular cell biology and genetics from İstanbul Kültür University, Turkey. He also gained experience in the cell biology wet-lab. He did a master’s degree in bioinformatics and systems biology at Gebze Technical University, Turkey. His research experience is about computational systems biology. He has been involved in the TÜBİTAK project to study neurodegenerative disease; analyzing omic-data with GEMs. In the Mardinoglu lab, Ali will be using a systems biology approach to understand the molecular mechanism of Glioblastoma disease.


Mengnan Shi @SciLifeLab
Email:
[email protected]

Mengnan Shi received her B.E degree in Biomedical Engineering at Central South University, China, and completed master degree in Molecular Technology in Life Science at KTH Royal Institute of Technology. Her research contributes to target-based drug discovery in NAFLD, including in silico drug discovery and in vitro drug screening. As a member of the Sysmedicine Lab in SciLifeLab, she is focusing on multi-omics data analysis as well as network analysis among tissues.
 


Xiya Song @SciLifeLab
Email:
[email protected]

Xiya Song graduated from the China Agricultural University with a B.Sc degree in Biological Science. Then she received her M.Sc degree in Molecular Techniques in Life Science at KTH Royal Institute of Technology. She has experience in multiple fields of biomedical research, including tumour immunology and single-cell RNA-sequencing. In her master’s thesis, she learned knowledge about systems biology and focused on eQTL-analysis and genomics analysis at Sysmedicine Group. In her doctoral study, she will analyse genomics data obtained from patients and identify potential pathogenic genetic alterations combined with the systems biology approach. The final aim is to discover potential drug targets and biomarkers.


Atakan Burak Ceyhan @King’s College London
Email:
[email protected]

Atakan Burak Ceyhan, MD received his bachelor’s degree from Istanbul University, Cerrahpasa Faculty of Medicine. After graduation, he worked as general practitioner and district health director at Ministry of Health, Turkey. He started his PhD at King’s Collage of London and joined the Mardinoglu Lab. Currently, his project is developing new therapies, discovering biomarkers and novel drug targets for sarcopenia. He will use systems biology approach to understand molecular pathophysiology of the disease.


Mengzhen [email protected]
Email:
[email protected]

Mengzhen Li received her Bachelor’s degree and Master’s degree in Medicine from Guangzhou University of Chinese Medicine. Currently, her project is adopting systems biology approach to understand the pathophysiological responses of metabolic disease.

 
 


MASTER PROJECTS


Jiaqi Lu @SciLifeLab
Email:
[email protected]

Jiaqi is currently in the second year of the Molecular Technique in Life Science master’s program, and she works as a project student in the group. She mainly works with method development in processing single cell RNA-seq datasets and seeks for a better way to stratify patients in precision medicine.

 
 


Xinmeng Liao @King’s College London
Email:
[email protected]

Xinmeng Liao graduated from Southern Medical University, China and received her Master’s degree in King’s College London, United Kingdom. She gained multiple knowledge about system biology approaches from her Master’s study. Currently, her project is constructing a computational pipeline for identifying potential drug targets and revealing the underlying mechanism of drug repurposing.

 
 


Xueqi Li @King’s College London
Email:
[email protected]

Xueqi Li received her Bachelor’s degree from Tianjin University of Science and Technology, China and Master’s degree from King’s College London, United Kingdom. Currently, her project is adopting systems biology approach to identify therapeutic target genes and drug repositioning in prostate adenocarcinoma.

 
 
 


FORMER LAB MEMBERS


  • Dr. Simon Lam, University of Cambridge
  • Dr. Muhammad Arif, The National Institutes of Health (NIH)
  • Dr. Amalyn Nain
  • Dr. Shazia Iqbal
  • Shuqi Chen
  • Dr. Battisti Umberto Maria
  • Dr. Chunxia Gao
  • Dr. Leticia Monjas
  • Dr. Josipa Matić
  • Dr. Anders Foller Füchtbauer
  • Dr. Alexandra Rodriguez Rivero
  • Dr. Munira Taj Muhammad
  • Stephen Doran
  • Mohamed Al Shobky
  • Elyas Mohammadi
  • Feride Eren, Karolinska Institutet
  • Jung Tae Kim
  • Kajetan Juszczak
  • Rui Benfeitas, National Bioinformatic Infrastructure of Sweden (NBIS)
  • Alen Lovric, Karolinska University Hospital
  • Beste Turanli, Marmara University
  • Natasa Sikanic, Karolinska University Hospital
  • Dorines Rosario, Kings College London
  • Nadia Karimpour, Kings College London
  • Dr. Gholamreza Bidkhori, Kings College London
  • Dr. Sunjae Lee, Kings College London
  • Dr. Zhengtao Liu, Zhejiang University
  • Dr. Fady Akladios, Charles Sturt University, Australia
  • Ida Larsson, Uppsala University
  • Sumit Deshmukh, University of Skövde
  • Dr. Kemal Sanli, University of Gothenburg
  • Ezgi Elmas, Mugla Sitki Kocman University, Turkey
  • Azadeh  Mohammad Pour, King’s College London
  • Baris Sadik, Bogazici University, Turkey
  • Christofer Boren, KTH – Royal Institute of Technology
  • Tim Kuijpers, Eindhoven University of Technology, Netherlands
  • Pisanu Buphamalai, KTH – Royal Institute of Technology
  • Dr. Bunjamin Memishi, Universidad Politecnica de Madrid

Group Photo


christmas1

christmas2